Combination Therapy with Platinum and Etoposide of Brain Metastases from Breast Carcinoma

Cocconi, Giorgio; Lottici, Renata; Bisagni, Giancarlo; Bacchi, M.; Tonato, Maurizio; Passalacqua, Rodolfo; Boni, C.; Belsanti, Virginio; P, Bassi

doi:10.3109/07357909009012049

Cited by 122 publications

(43 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results demonstrated that the BEEP regimen had a CNS-ORR of 77%, which was considerably higher than expected. Previous studies using the combination of etoposide and cisplatin have indicated an overall response rate of 38% to 55% according to WHO criteria for brain metastasis of breast cancer patients; however, only 27% to 45% of enrolled patients received prior systemic chemotherapy for metastatic disease and 0% to 9% of patients underwent WBRT before participating in these studies (5,6). The high response rate in our study indicates that a preconditioning treatment of bevacizumab enhanced the antitumor effect of etoposide and cisplatin, even in metastatic brain tumors.…”

Section: Discussionmentioning

confidence: 99%

“…However, several studies have suggested that the BBB can be partially disrupted during the growth of a metastatic brain tumor, thus allowing a certain amount of chemotherapeutic drugs to be delivered to the brain tumor lesion (4). Chemotherapy combining etoposide and cisplatin demonstrated an overall response rate of 38% to 55% in patients with brain metastasis of breast cancer who had not received WBRT (5,6). Prospective clinical studies that have focused on treating breast cancer with progressive brain metastases after WBRT are limited to HER2-positive subtype.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

Chen

Lin

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: We hypothesized that a window period between bevacizumab and cytotoxic agents may enhance drug delivery into tumor tissue through bevacizumab-induced vascular normalization in patients with brain metastases of breast cancer (BMBC).Experimental Design: A single-arm phase II study was conducted in which BMBC patients refractory to whole-brain radiotherapy (WBRT) were enrolled. In a 21-day cycle, patients received bevacizumab (15 mg/kg) on day 1, which, with a 1-day window period, was followed by etoposide (70 mg/m 2 /day; days 2-4) and cisplatin (70 mg/m 2 ; day 2; BEEP regimen). The BEEP regimen was administered for a maximum of 6 cycles. The primary endpoint was the central nervous system (CNS)-objective response rate according to volumetric response criteria.Results: A total of 35 patients were enrolled between January 2011 and January 2013. The median age was 54.3 years (range, 33-75); 19 patients (54.3%) had an Eastern Cooperative Oncology Group performance status of 2 or 3. Twenty-seven patients [77.1%; 95% confidence interval (CI), 59.9-89.6] achieved a CNS-objective response, including 13 patients (37.1%) with a !80% volumetric reduction of CNS lesions. With a median follow-up of 16.1 months, the median CNS progression-free survival and overall survival times were 7.3 months (95% CI, 6.5-8.1) and 10.5 months (95% CI, 7.8-13.2), respectively. Common grade 3 or 4 toxicities included neutropenia (30.8%) and infection (21.3%).Conclusions: By administering bevacizumab 1 day before etoposide and cisplatin, the BEEP regimen appeared highly effective in BMBC refractory to WBRT. Further study of vascular normalization window concept is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

Chen

Lin

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Há melhora em até 55% dos doentes com metástases de carcinoma de mama 54,177 . Os tumores quimiossensíveis podem ser resistentes à quimioterapia não apenas por causa da atuação da barreira hemato encefálica 170 , mas também pelo fato de muitas metástases serem mais resistentes que a lesão primária 201 .…”

Section: Metástases Encefálicasunclassified

Untitled

2002

Arq Bras Neurocir

View full text Add to dashboard Cite

RESUMO PALAVRAS-CHAVEBraquiterapia. Radioterapia. Tumores encefálicos. ABSTRACT Interstitial radiotherapy for treatment of brain tumors IntroduçãoAs neoplasias do encéfalo estão entre a sexta e oitava causas mais freqüentes de lesões intracranianas dos adultos e a segunda causa mais comum de doença neurológica crônica em pediatria. Os tumores primários do encéfalo correspondem a 2% dos óbitos provocados pelo câncer. São responsáveis por 20% dos tumores malignos diagnosticados antes dos 15 anos de idade e por, aproximadamente, 30% das mortes na sociedade ocidental 118 .Graças à adoção de recursos tecnológicos mais apropriados, à execução de intervenções terapêuticas precoces e à adoção de tratamentos adjuvantes mais adequados, os resultados das terapias para as neoplasias encefálicas tornaram-se mais favoráveis. Entre esses recursos, destacam-se a delineação das lesões com novas técnicas de aquisição de imagem acopladas aos princípios de estereotaxia, a neuronavegação, a eletrofisiologia intra-operatória, a ressonância magnética realizada durante o ato operatório e as conquistas recentes nas áreas de quimioterapia, radioterapia, biologia molecular e genética dos tumores encefálicos.Entretanto, apesar do entusiasmo com a aplicação dos novos conhecimentos em neurooncologia -como a terapia gênica e a imunoterapia -, os procedimentos clássicos fundamentados em cirurgias radicais ou paliativas e em radioterapia e, eventualmente, em quimioterapia são ainda os melhores instrumentos para o tratamento da maioria das lesões neoplásicas primárias ou secundárias do encéfalo. Desses, os procedimentos de radioterapia são considerados um dos mais efetivos, isoladamente ou complementando tratamentos cirúrgicos ou quimioterápicos 22 .

show abstract

“…Зарегистрировано 12 полных регрессий, 21 частичная регрессия. Средняя продолжи-тельность жизни больных составила 31-58 недель (9,12).…”

unclassified

Drug Therapy of Breast Cancer Patients With Metastatic Brain Lesions.

Насхлеташвили¹,

Gorbunova²,

Москвина³

et al. 2015

Zlokač. opuholi

View full text Add to dashboard Cite

Combination Therapy with Platinum and Etoposide of Brain Metastases from Breast Carcinoma

Cited by 122 publications

References 25 publications

Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

Untitled

Drug Therapy of Breast Cancer Patients With Metastatic Brain Lesions.

Contact Info

Product

Resources

About